Plecanatide Does Not Help with Flatulence
Plecanatide is not indicated for flatulence and has no evidence supporting its use for this symptom. The available evidence demonstrates that plecanatide is FDA-approved specifically for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults, with efficacy focused on improving bowel movements, stool consistency, and abdominal pain—not flatulence 1.
Why Plecanatide Won't Address Flatulence
Plecanatide works as a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates GI transit 2. This mechanism:
- Increases bowel movement frequency (mean difference of 1.1 CSBMs per week and 1.66 SBMs per week) 2
- Softens stool consistency through enhanced chloride and bicarbonate secretion into the intestinal lumen 1
- May improve abdominal pain and bloating in IBS-C patients 2, 3
However, flatulence is not among the symptoms that plecanatide addresses. The comprehensive 2023 AGA-ACG guidelines on pharmacological management of CIC make no mention of flatulence as an outcome measure in any of the three 12-week randomized controlled trials evaluating plecanatide 2.
What the Evidence Actually Shows
The pooled data from clinical trials evaluated these specific outcomes 2:
- Complete spontaneous bowel movements (CSBMs) per week
- Spontaneous bowel movements (SBMs) per week
- Stool consistency (Bristol Stool Form Scale)
- Quality of life scores
- Abdominal pain, bloating, cramping, discomfort, and fullness (in IBS-C trials) 3, 4
Flatulence was neither measured nor reported as an outcome in any trial.
Important Clinical Considerations
What Plecanatide Actually Does
In adults with severe constipation, plecanatide 3 mg significantly improved:
- Durable CSBM response rates (20.9% vs 11.3% placebo in CIC) 5
- Overall response rates (33.0% vs 19.0% placebo in IBS-C with severe constipation) 5
- Median time to first CSBM 5
The Primary Side Effect
Diarrhea is the most common adverse event (4.3% with 3 mg, 4.0% with 6 mg vs 1.0% placebo), leading to discontinuation in 1.2-1.4% of patients 2, 3, 4. This could theoretically worsen gas-related symptoms rather than improve them.
Potential Misunderstanding
If the patient has IBS-C with bloating, plecanatide may help the bloating component as a secondary benefit 2, 3. However, this is distinct from flatulence (gas passage), and the drug should be prescribed for the constipation and abdominal pain—not for gas symptoms specifically.
Bottom Line
Do not prescribe plecanatide for flatulence alone. The drug has a strong recommendation for use in adults with CIC or IBS-C who have not responded to over-the-counter agents (strong recommendation, moderate certainty of evidence) 2, but only when the primary symptoms are constipation with or without abdominal pain. If flatulence is the predominant complaint without significant constipation, alternative approaches targeting gas production or intestinal microbiota would be more appropriate.